Vascular complications such as bleeding due to gastrointestinal telangiectatic anomalies, pulmonary arteriovenous malformations, hepatopulmonary syndrome, and retinal vessel abnormalities are being reported in patients with telomere biology disorders (TBDs) more frequently than previously described. The international clinical care consortium of telomere-associated ailments and family support group Dyskeratosis Congenita Outreach, Inc. held a workshop on vascular abnormalities in the TBDs at the National Cancer Institute in October 2017. Clinicians and basic scientists reviewed current data on vascular complications, hypotheses for the underlying biology and developed new collaborations to address the etiology and clinical management of vascular complications in TBDs.
Background
The telomere biology disorders (TBDs) manifest with a wide array of complex medical complications and are caused by germline pathogenic variants in telomere biology genes [1] [2] [3] [4] . These disorders have also been termed short telomere syndromes [3] . Patients with dyskeratosis congenita (DC), the prototypic TBD, are often clinically characterized by the triad of lacy reticular skin pigmentation, oral leukoplakia, and dysplastic nails. They are at high risk of developing bone marrow failure, pulmonary fibrosis, avascular necrosis of the hips or shoulders, esophageal stenosis, and other medical problems including a high lifetime risk of specific cancers [5, 6] . The discovery of germline pathogenic variants in DKC1 (encoding dyskerin) as the cause of X-linked recessive DC showed, for the first time, that aberrations in telomere biology resulting in very short telomeres could cause clinically significant human phenotypes [7, 8] . Since then, 13 additional genes have been associated with DC and related TBDs with de novo, autosomal dominant, and autosomal recessive inheritance patterns ( Fig. 1) [1, [9] [10] [11] .
The clinical spectrum of TBDs has expanded as discoveries of the genetic causes have grown (Table 1) . Some patients, primarily those with predominantly autosomal dominant disease due to TERT, TERC, PARN, or RTEL1 mutations, may develop just one feature of DC in adulthood in the absence of the mucocutaneous triad [1] [2] [3] [12] [13] [14] [15] [16] . Other patients, including those with DKC1 mutations, de novo TINF2 mutations, or autosomal recessive disease may present at an earlier age. Those with Hoyeraal-Hreidarsson syndrome, a variant of DC that has features of immunodeficiency and cerebellar hypoplasia, or Revesz syndrome that encompasses features of DC with exudative retinopathy and intracranial complications [1, 6, 17] , may present in infancy. Coats plus, a rare autosomal recessive disease, typically includes intracranial calcifications with associated brain cysts, gastrointestinal (GI) bleeding due to telangiectasias, retinal vascular abnormalities, and abnormal bone healing [18, 19] . Coats plus was linked with TBD when patients with DC were also found to have mutations in CTC1 [20, 21] .
New clinical presentations are now being recognized in patients with TBDs, likely due to improvements in supportive care and survival into adulthood allowing for the progression of disease. For example, hepatopulmonary syndrome, pulmonary shunting, and development of pulmonary 
Are vascular complications more frequent than previously appreciated?
Bleeding due to vascular telangiectatic anomalies of the GI tract is the most common cause of death in patients with Coats plus [18, 26] but there are little data on the clinical management [27] [28] [29] . Workshop attendees reported clinically significant GI bleeding in 16 patients with DC, a phenotype rarely reported in the over 100 years of DC/TBD literature (Fig. 2) . The majority of patients discussed at the workshop had a germline mutation in TINF2. Patients with mutations in TERC, TERT, or CTC1, and unknown genetic cause of disease were also reported. The time from diagnosis of DC or HCT to first GI bleed ranged from months to years. GI bleeding could be present at diagnosis of a TBD and was not solely as a post-HCT complication. Upper endoscopy revealed that most patients had erythematous or telangiectatic lesions in the lumen of the stomach or small intestine. The diagnosis of gastric antral vascular ectasia (GAVE) was applied to some of these cases during their work-up.
The presence of vascular telangiectasia could also be compounded by portal hypertensive gastropathy and the development of esophageal varices due to progressive portal hypertension. Whereas esophageal varices are amenable to banding, vascular hypertensive ectasia of the stomach is much more difficult to treat. However, only one of the patients with GI bleeding discussed at the workshop had a history of GI bleeding due to esophageal varices. Workshop participants reported the anecdotal use of estrogen, progesterone, propranolol, octreotide, thalidomide, budesonide, bevacizumab, argon plasma coagulation, and radiofrequency ablation, but there was insufficient data to reach consensus on how to best manage GI bleeding in TBD patients.
Exudative vitreoretinopathy is characteristic of Coats plus and Revesz syndrome but there are limited data on the specific ophthalmologic complications in patients with DC [30] . Case presentations at the workshop showed a wide array of retinal vascular diseases in patients with DC. Laser photocoagulation of severe retinopathy is currently the preferred mode of treatment for retinal vascular disease in DC/TBD. The laser is applied to the avascular peripheral retina, which presumably decreases vascular permeability factors and proangiogenic factors that may be contributing to progressive vasculopathy and pathologic neovascularization [31, 32] . Intravitreal injection of bevacizumab is a treatment option [33] . The retinopathy in DC/TBD patients can result in a tractional retinal detachment and vitreous hemorrhage. Such advanced pathology is treated with vitreoretinal surgery to clear the visual axis and reattach the retina. However, advanced and chronic retinal detachment may become inoperable. Early screening of patient with TBD with ultra-widefield fluorescein angiography is important to detect these subtle vascular abnormalities earlier in the disease course to prevent complications.
Overall, vascular complications including GI bleeding and retinal vascular disease appear to be more widespread in TBDs than expected. Patients with GI bleeding did not necessarily have features of Coats plus and those with exudative vitreoretinopathy were not consistently diagnosed with Revesz syndrome. Table 2 illustrates some of the key questions and potential answers in the setting of vascular complications in TBDs. Multi-disciplinary, international collaborative studies between patients, clinicians, and basic scientists are essential to improving understanding of all rare diseases, and especially of unique complications in these diseases. The workshop also featured talks by two basic scientists in order to facilitate building bridges between clinicians taking care of patients with DC/TBDs and basic scientists making novel contributions to the telomere field. Dr. Utz Herbig, Rutgers New Jersey Medical School, presented his research on telomeres and wound healing. There is a growing appreciation of the impact of cellular senescence on wound healing, including via telomere dysfunction-induced senescence and the resulting senescence associated secretory phenotypes (SASP) [34] . The SASPs are pro-inflammatory and postulated to be an important aspect of vascular dysfunction and risk of cardiovascular disease [35] . Since telomeres are sensitive to oxidative damage, it is possible that very short telomeres, such as those seen in TBDs, are even more susceptible to the SASP environment.
Challenges and opportunities in clinical studies of rare TBDs
Although not yet studied, SASP in TBDs could result in abnormal wound healing or cellular responses to inflammation. Another possibility that was raised in the discussion is that short telomeres impair the healing process through cell-autonomous defects.
There may be biological connections underlying the TBDs and vascular complications. For example, the Wnt/ beta-catenin pathway is implicated in vascular development and homeostasis [36] . To explore this further, Dr. Brad Johnson, University of Pennsylvania, was invited to present his research on Wnt/β-catenin signaling and telomere capping. He discussed a possible role of this pathway in TBDs [37, 38] . Supporting the importance of a link between abnormal Wnt/β-catenin signaling and vasculopathy driven by telomere dysfunction is the fact that the retinal vascular abnormalities of two diseases caused by mutations in Wnt pathway signaling components, familial exudative vitreoretinopathy, and Coat's disease (from which Coat's plus derives its name) are reminiscent of the retinal abnormalities observed in TBDs [39] [40] [41] [42] . Additional preclinical studies are required, but it is intriguing to speculate on whether targeting Wnt/beta-catenin could yield novel therapeutics for TBDs.
The workshop also emphasized the importance of multi-disciplinary collaborations and featured an exploratory study of airway epithelial stem/progenitor cells in one patient with DC. Drs. Susan Reynolds and Don Hayes, Nationwide Children's Hospital and The Ohio State University, presented preliminary data showing reduced proliferative capacity of these cells in the patient compared with controls. These data raise the possibility that telomere shortening decreases airway basal epithelial stem/ progenitor cell life-span and contributes to lung pathology in TBD patients. In the clinical evaluation of this particular patient, a significantly elevated vascular endothelial growth factor A (VEGFA) level was found in peripheral blood. Based on published literature, the potential link between basal epithelial stem/progenitor cells and vascular biology of the lung is a high expression of VEGFA by these progenitor cells along with VEGFA-mediated crosstalk between these progenitor cells and the endothelium. This cellular interaction appears to modulate endothelial activation and in turn stimulates and sustains basal epithelial stem/progenitor cell growth [43] .
Clinicians, researchers, patient groups, and other stakeholders are in a key information gathering phase to understand TBD-associated complications. Collaborative efforts have grown significantly since the first DC-focused workshop in 2008 [4] . The CCC TAA facilitated peer-review of the first edition of "Clinical Care and Diagnosis of Dyskeratosis Congenita and TBDs" guidelines book (https ://teamt elome re.org/resou rces/#resea rch) in close collaboration with DCO, stimulated collaborative relationships towards a multi-center HCT trial (ClinicalTrials.gov Identifier: NCT01659606), and enabled a case series on PAVM in DC [22] . The consortium is now conducting a systematic retrospective case series of GI bleeding in patients with TBDs to understand the approaches to diagnosis and management of this complex phenotype.
Conclusions
The clinical complications caused by aberrant telomere biology are complex and our understanding of these is still developing. The phenotypic spectrum is evolving as TBDs continue to be connected through genetics, and as clinicians and patient advocacy groups join forces to rigorously document disease manifestations and natural history. Clinicians and basic scientists are leveraging this information to reappraise potential pathophysiological mechanisms linking telomere biology to disease. It is worthwhile to consider that defects in vascular biology caused by telomere dysfunction provide a unifying mechanism driving disparate phenotypic manifestations across the TBD spectrum.
